Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 256 Breast Neoplasms 173 Neoplasms 169 Colorectal Neoplasms 155 Neoplasm Metastasis 126 Melanoma 120 Recurrence 118 Prostatic Neoplasms 118 Leukemia, Myeloid, Acute 117 Pancreatic Neoplasms 115 Ovarian Neoplasms 112 Multiple Myeloma 104 Lung Neoplasms 95 Stomach Neoplasms 92 Squamous Cell Carcinoma of Head and Neck 86 Triple Negative Breast Neoplasms 85 Glioblastoma 81 Lymphoma 77 Lymphoma, Non-Hodgkin 75 Lymphoma, Large B-Cell, Diffuse 65 Precursor Cell Lymphoblastic Leukemia-Lymphoma 64 Carcinoma, Renal Cell 64 Advanced Solid Tumor 59 Endometrial Neoplasms 58 Carcinoma, Hepatocellular 58 Small Cell Lung Carcinoma 55 Uterine Cervical Neoplasms 53 Sarcoma 53 Myelodysplastic Syndromes 51 Leukemia 50

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Anal Cancer Metastatic × 1 year × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡